Key result
Direct oral anticoagulant levels can be quantified using specific assays like Hemoclot and calibrated chromogenic anti-FXa assays, though traditional coagulation tests remain useful.
Answers are grounded in this paper and cite their sources.
While DOACs do not require routine monitoring, specific assays such as Hemoclot, ecarin-based, and calibrated chromogenic anti-FXa assays are suitable for quantifying drug levels when clinically necessary.
Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor, dabigatran, and the direct factor Xa (FXa) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for thromboembolism prevention and treatment. These drugs do not require routine coagulation monitoring but, in some circumstances, measurement of drug level or anticoagulant effect may be necessary. Although traditional coagulation tests lack analytical sensitivity and specificity, they are widely available and inexpensive, and can provide useful information regarding the residual anticoagulant effect of DOACs. Hemoclot® and ecarin-based assays can be used to quantify dabigatran level and calibrated chromogenic anti-FXa assays are suitable for measuring rivaroxaban, apixaban and edoxaban levels, but these tests are not yet widely available.
No takes yet. Share an insight, caveat, or question.
Dale et al. (2015) conducted a review in Thromboembolism. Direct oral anticoagulants (DOACs) was evaluated. Direct oral anticoagulant levels can be quantified using specific assays like Hemoclot and calibrated chromogenic anti-FXa assays, though traditional coagulation tests remain useful.
Synapse has enriched 10 related papers. Consider them for comparative context: